Humana Expands Use of the Inovalon ONE® Platform

Rhea-AI Summary

Inovalon (Nasdaq: INOV) has expanded its partnership with Humana to implement a Vaccine Adherence Program. This initiative, built on the Inovalon ONE® Platform, aims to enhance immunization adherence among health plan members by utilizing data integration and analysis aligned with CDC guidelines. The program is projected to improve health outcomes and quality ratings while reducing costs associated with vaccine-preventable diseases. The ongoing collaboration dates back to 2019, focusing on member health insights and comprehensive healthcare solutions.

Positive

• Expansion of partnership with Humana to implement Vaccine Adherence Program.
• Utilization of Inovalon ONE® Platform to enhance data integration and analysis.
• Potential for improved health outcomes and reduced costs from vaccine-preventable diseases.

Negative

• None.

Leading National Health Plan to Implement Vaccine Adherence Program

BOWIE, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, and Humana (NYSE: HUM), a leading national consumer-focused, technology-driven health plan known for its commitment to innovation, today announced the expansion of their collaboration in a focus on vaccine adherence.

Under the engagement, Inovalon will implement the Inovalon ONE^® Platform Vaccine Adherence Program, leveraging established healthcare ecosystem connectivity, data integration, normalization, and analyses to assess clinical applicability and adherence of health plan members to applicable Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) immunization schedules and guidelines. Analytical insights delivered through the data-driven program will inform member engagement and disease education efforts to promote uptake of recommended vaccines, resulting in improved health outcomes, quality ratings and overall public health, as well as significant economic benefits stemming from reductions in vaccine-preventable disease incidence and associated treatment costs. 

The broader Inovalon and Humana engagement dates back to early 2019 with the implementation of a configuration of the Inovalon ONE^® Platform focused on achieving advanced insight into member conditions and the subsequent empowering of data-driven initiatives to benefit Humana’s Commercial membership. A leading specialty pharmacy operator, Humana expanded the relationship later in 2019 to include Inovalon’s ScriptMed^® Cloud offering, a configuration of the Inovalon ONE^® Platform designed to combine superior analytically driven care protocols with superior quality, operational processes, and cost efficiencies for pharmacies. In early 2020, Humana added Inovalon’s Virtual Health Visit capabilities and later in 2020 expanded the application of the Inovalon ONE^® Platform to Humana’s Medicare membership.

“We are very pleased and appreciative to expand our relationship with such an industry innovator as Humana,” said Keith Dunleavy, M.D., chief executive officer of Inovalon. “Humana’s commitment to their members’ quality of care as well as their commitment to partnership in progressing programs together has been remarkable.”

About Inovalon

Inovalon is a leading provider of cloud-based platforms empowering data-driven healthcare. Through the Inovalon ONE^® Platform, Inovalon brings to the marketplace a national-scale capability to interconnect with the healthcare ecosystem, aggregate and analyze data in real time, and empower the application of resulting insights to drive meaningful impact at the point of care. Leveraging its Platform, unparalleled proprietary datasets, and industry-leading subject matter expertise, Inovalon enables better care, efficiency, and financial performance across the healthcare ecosystem. From health plans and provider organizations, to pharmaceutical, medical device, and diagnostics companies, Inovalon’s unique achievement of value is delivered through the effective progression of “Turning Data into Insight, and Insight into Action^®.” Supporting thousands of clients, including all 25 of the top 25 U.S. health plans, 22 of the top 25 global pharma companies, 19 of the top 25 U.S. healthcare provider systems, and many of the leading pharmacy organizations, device manufacturers, and other healthcare industry constituents, Inovalon’s technology platforms and analytics are informed by data pertaining to more than one million physicians, 574,000 clinical facilities, 332 million Americans, and 61 billion medical events. For more information, visit www.inovalon.com.

Contact:

Kim E. Collins
Senior Vice President, Corporate Communications
kcollins@inovalon.com
301-809-4000 x1473

Hulus Alpay
Vice President, Investor Relations
halpay@inovalon.com
301-809-4000 x1237

FAQ

What is the main focus of Inovalon's new collaboration with Humana?

The collaboration focuses on implementing a Vaccine Adherence Program to enhance immunization adherence among health plan members.

How does the Inovalon ONE® Platform contribute to the Vaccine Adherence Program?

The Inovalon ONE® Platform facilitates data integration and analysis to assess adherence to CDC immunization guidelines.

When did Inovalon and Humana first collaborate?

Inovalon and Humana began their collaboration in early 2019, initially focusing on member health insights.

What are the expected benefits of the Vaccine Adherence Program?

The program aims to improve health outcomes, enhance quality ratings, and reduce costs associated with vaccine-preventable diseases.

What is the stock symbol for Inovalon?

The stock symbol for Inovalon is INOV.